Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open, single dose, antitumor effect study of 2-hydroxyflutamide as a controlled release product (Liproca Depot), injected into the prostate in patients with localized prostate cancer.

Next Previous
Trial Profile

An open, single dose, antitumor effect study of 2-hydroxyflutamide as a controlled release product (Liproca Depot), injected into the prostate in patients with localized prostate cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydroxyflutamide (Primary)
  • Indications Prostate cancer
  • Focus Pharmacodynamics
  • Sponsors LIDDS

Most Recent Events

  • 08 Feb 2018 According to a Lidds Pharma media release, results from this and the LPC-002 trials have been published in The Journal of Urology in December 2016.
  • 10 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 13 Jan 2015 Planned End Date changed from 21 Feb 2012 to 1 May 2016, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top